NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo
NanoViricides, Inc NNVC
$1.52
▼ -1.94%
($-0.03)
Open
$1.52
Prev Close
$1.55
Day Range
$1.51 – $1.60
52W Range
$0.85 – $2.23
Market Cap
$38.61M
Beta
1.75
EPS (TTM)
$-0.44
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2004-08-12 |
| Shares Out. | 25,400,000 |
| Website | nanoviricides.com/ ↗ |
| Phone | 12039376137 |
| Employees | 7 |
| Net Income | -$2.0M |
| Free Cash Flow | -$7.4M |
| Total Assets | $10.2M |
| Total Liabilities | $1.1M |
| Equity | $9.2M |
About NanoViricides, Inc
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
NanoViricides, Inc is a publicly traded company under the ticker symbol NNVC on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)